^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-361175

    i
    Company:
    Betta Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (NCT05329298)
    Phase 1/2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    04/15/2022
    Initiation :
    07/21/2021
    Primary completion :
    06/30/2023
    Completion :
    12/31/2023
    EGFR
    |
    EGFR mutation
    |
    BPI-361175